Inhibikase Therapeutics, Inc. (IKT) stock
IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.38−0.07 (-4.83%)
Close on Nov 17, 2026Market cap $192.56MP/E –Yield –
Inhibikase Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Inhibikase Therapeutics's profit margin for the twelve months ending Sep 30, 2024 was -1956524900.0%. For fiscal 2023 it was -7304.7%, against -14625.9% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -7304.7% | +7321.1 |
| FY2022 | Dec 31, 2022 | -14625.9% | −14149.0 |
| FY2021 | Dec 31, 2021 | -476.9% | −69.1 |
| FY2020 | Dec 31, 2020 | -407.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | -417794000.0% | −417787268.3 |
| Q3 FY2023 | Sep 30, 2023 | -5775.1% | +55870.2 |
| Q2 FY2023 | Jun 30, 2023 | -4963.5% | +65853.7 |
| Q1 FY2023 | Mar 31, 2023 | -6940.0% | +3141.4 |
| Q4 FY2022 | Dec 31, 2022 | -6731.7% | −6538.3 |
| Q3 FY2022 | Sep 30, 2022 | -61645.4% | −61458.0 |
| Q2 FY2022 | Jun 30, 2022 | -70817.1% | −70108.3 |
| Q1 FY2022 | Mar 31, 2022 | -10081.5% | −8301.7 |
| Q2 FY2021 | Jun 30, 2021 | -193.4% | −1.3 |
| Q1 FY2021 | Mar 31, 2021 | -187.4% | +14.8 |
| Q4 FY2020 | Dec 31, 2020 | -708.8% | – |
| Q3 FY2020 | Sep 30, 2020 | -1779.7% | – |
| Q2 FY2020 | Jun 30, 2020 | -192.1% | – |
| Q1 FY2020 | Mar 31, 2020 | -202.2% | – |
See a number that looks wrong?